Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang 150001, P.R. China.
Department of Anaesthesiology, The Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang 150040, P.R. China.
Oncol Rep. 2018 Dec;40(6):3611-3624. doi: 10.3892/or.2018.6776. Epub 2018 Oct 9.
Circulating microRNAs (miRNAs) are promising diagnostic markers in various types of cancers, including papillary thyroid carcinoma (PTC). However, there is sparse information reported with regards to miRNA expression in papillary thyroid microcarcinoma (PTMC) or concerning the role of a combination of miRNAs and ultrasound (US) in the diagnosis of PTMC before surgery. Therefore, we designed a study that aimed to evaluate miRNA expression levels and their potential associations with US findings and determine whether miRNAs could be used as diagnostic and prognostic biomarkers of PTMC. miR‑222, miR‑221, miR‑146b and miR‑21 levels were determined using reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) in serum from 58 patients with PTMC and 47 with PTC, 35 patients with benign thyroid nodules (BTN) and 40 control subjects. Expression levels of the four miRNAs in serum were evaluated before and after surgery. The results indicated that miR‑222, miR‑221, miR‑146b and miR‑21 expression levels were higher in the PTMC samples than in those from the BTN and control groups and the combination of miRNAs and US had a high sensitivity and specificity for discrimination between BTN and PTMC by receiver operating characteristic (ROC) curve analysis and improved the accuracy of diagnosis of PTMC before surgery. In addition, serum miRNA expression levels were significantly related to poor prognostic factors including metastatic lymph nodules (MLNs), multifocal and bilateral lesions, advanced stage and high‑risk PTMC patients. The miRNA expression levels in serum from PTMC patients were rapidly reduced after surgery compared with levels before surgery. In addition, we also analyzed the miRNA expression levels in serum from patients who were divided into two groups according to factors indicating a good or poor prognosis associated with PTMC after surgery. The results suggested that after surgery, the miR‑222, miR‑146b and miR‑21 expression levels were significantly higher in the poor prognosis group compared with these levels in the good prognosis group. Serum miRNA expression levels helped distinguish between benign and malignant nodules and were associated with a poor prognosis in PTMC. Circulating miRNAs may be useful as follow‑up biomarkers and as diagnostic and prognostic tools.
循环 microRNAs(miRNAs)是各种类型癌症,包括甲状腺乳头状癌(PTC)的有前途的诊断标志物。然而,关于甲状腺微小乳头状癌(PTMC)中 miRNA 的表达或关于 miRNA 和超声(US)组合在手术前诊断 PTMC 中的作用的信息很少。因此,我们设计了一项研究,旨在评估 miRNA 表达水平及其与 US 发现的潜在关联,并确定 miRNA 是否可作为 PTMC 的诊断和预后生物标志物。使用逆转录-定量聚合酶链反应(RT-qPCR)在 58 例 PTMC 患者和 47 例 PTC 患者、35 例良性甲状腺结节(BTN)患者和 40 例对照者的血清中测定 miR-222、miR-221、miR-146b 和 miR-21 水平。评估了这四种 miRNA 在血清中的表达水平在手术前后。结果表明,PTMC 样本中的 miR-222、miR-221、miR-146b 和 miR-21 表达水平高于 BTN 和对照组,miRNA 和 US 的组合通过接收者操作特征(ROC)曲线分析对 BTN 和 PTMC 之间的区分具有高敏感性和特异性,并提高了术前 PTMC 的诊断准确性。此外,血清 miRNA 表达水平与不良预后因素显著相关,包括转移性淋巴结(MLNs)、多灶性和双侧病变、晚期和高危 PTMC 患者。与术前相比,PTMC 患者术后血清中 miRNA 表达水平迅速降低。此外,我们还根据与术后 PTMC 预后相关的因素将血清中 miRNA 表达水平分析为两组。结果表明,术后,预后不良组的 miR-222、miR-146b 和 miR-21 表达水平明显高于预后良好组。血清 miRNA 表达水平有助于区分良性和恶性结节,并与 PTMC 的不良预后相关。循环 miRNA 可能作为随访生物标志物以及诊断和预后工具有用。